DE69735433D1 - Verfahren zur herstellung von substituierten pyridinen - Google Patents

Verfahren zur herstellung von substituierten pyridinen

Info

Publication number
DE69735433D1
DE69735433D1 DE69735433T DE69735433T DE69735433D1 DE 69735433 D1 DE69735433 D1 DE 69735433D1 DE 69735433 T DE69735433 T DE 69735433T DE 69735433 T DE69735433 T DE 69735433T DE 69735433 D1 DE69735433 D1 DE 69735433D1
Authority
DE
Germany
Prior art keywords
production
substituted pyridines
pyridines
substituted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69735433T
Other languages
German (de)
English (en)
Inventor
Michael Devries
Lee Dow
Wayne Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Application granted granted Critical
Publication of DE69735433D1 publication Critical patent/DE69735433D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/73Unsubstituted amino or imino radicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/75Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69735433T 1996-11-14 1997-11-03 Verfahren zur herstellung von substituierten pyridinen Expired - Lifetime DE69735433D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3088096P 1996-11-14 1996-11-14
PCT/IB1997/001367 WO1998021184A1 (en) 1996-11-14 1997-11-03 Process for substituted pyridines

Publications (1)

Publication Number Publication Date
DE69735433D1 true DE69735433D1 (de) 2006-05-04

Family

ID=21856496

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69735433T Expired - Lifetime DE69735433D1 (de) 1996-11-14 1997-11-03 Verfahren zur herstellung von substituierten pyridinen

Country Status (32)

Country Link
US (1) US6291489B1 (US06291489-20010918-C00045.png)
EP (1) EP0938476B1 (US06291489-20010918-C00045.png)
JP (1) JP3510635B2 (US06291489-20010918-C00045.png)
KR (1) KR20000053314A (US06291489-20010918-C00045.png)
CN (1) CN1237160A (US06291489-20010918-C00045.png)
AP (1) AP805A (US06291489-20010918-C00045.png)
AR (1) AR010584A1 (US06291489-20010918-C00045.png)
AT (1) ATE319687T1 (US06291489-20010918-C00045.png)
AU (1) AU4634697A (US06291489-20010918-C00045.png)
BG (1) BG103393A (US06291489-20010918-C00045.png)
BR (1) BR9712951A (US06291489-20010918-C00045.png)
CA (1) CA2270386C (US06291489-20010918-C00045.png)
CO (1) CO4930261A1 (US06291489-20010918-C00045.png)
DE (1) DE69735433D1 (US06291489-20010918-C00045.png)
EA (1) EA199900375A1 (US06291489-20010918-C00045.png)
GT (1) GT199700118A (US06291489-20010918-C00045.png)
HR (1) HRP970612A2 (US06291489-20010918-C00045.png)
ID (1) ID18898A (US06291489-20010918-C00045.png)
IL (1) IL129688A0 (US06291489-20010918-C00045.png)
IS (1) IS5029A (US06291489-20010918-C00045.png)
MA (1) MA24401A1 (US06291489-20010918-C00045.png)
MY (1) MY132507A (US06291489-20010918-C00045.png)
NO (1) NO992296L (US06291489-20010918-C00045.png)
OA (1) OA11044A (US06291489-20010918-C00045.png)
PA (1) PA8441401A1 (US06291489-20010918-C00045.png)
PE (1) PE10299A1 (US06291489-20010918-C00045.png)
TN (1) TNSN97172A1 (US06291489-20010918-C00045.png)
TR (1) TR199901063T2 (US06291489-20010918-C00045.png)
UY (1) UY24774A1 (US06291489-20010918-C00045.png)
WO (1) WO1998021184A1 (US06291489-20010918-C00045.png)
YU (1) YU22099A (US06291489-20010918-C00045.png)
ZA (1) ZA9710186B (US06291489-20010918-C00045.png)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9909555A (pt) * 1998-04-08 2000-12-19 Novartis Ag Novartis S A Novar Herbicidas
US6090942A (en) * 1998-10-15 2000-07-18 Pfizer Inc. Process and intermediates for a β3 -adrenergic receptor agonist
KR20010102198A (ko) * 1999-02-16 2001-11-15 후루타 타케시 치환 아세틸피리딘 유도체 및 그를 이용하는 광학활성 β3작용제 중간체의 제조 방법
US6455734B1 (en) * 2000-08-09 2002-09-24 Magnesium Diagnostics, Inc. Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states
DE60015036T2 (de) * 1999-07-23 2006-03-02 Pfizer Products Inc., Groton Zwischenprodukte und ein Verfahren zur Herstellung von beta3-Adrenergischer Rezeptor-Agoniste
EP1454899A1 (en) * 2001-10-17 2004-09-08 Kaneka Corporation Process for preparation of (s)-alpha-halome thylpyridine methanol derivatives
AU2003209527A1 (en) 2002-02-27 2003-09-09 Pfizer Products Inc. Crystal forms of (r)-2-(2-(4-oxazol-4-yl-phenoxy)-ethylamino)-1-pyridin-3-yl-ethanol
US6864268B2 (en) 2002-02-27 2005-03-08 Pfizer Inc. β3 adrenergic receptor agonists
MXPA04008298A (es) * 2002-02-27 2004-11-26 Pfizer Prod Inc Procesos e intermedios utiles en la preparacion de agonistas de receptor beta-3 adrenergico.
EP1424079A1 (en) * 2002-11-27 2004-06-02 Boehringer Ingelheim International GmbH Combination of a beta-3-receptor agonist and of a reuptake inhibitor of serotonin and/or norepinephrine
WO2004099189A1 (en) 2003-05-09 2004-11-18 F. Hoffmann-La Roche Ag Methyl indoles and methyl pyrrolopyridines as alph-1 adrenergic agonists
US7977359B2 (en) 2005-11-04 2011-07-12 Amira Pharmaceuticals, Inc. 5-lipdxygenase-activating protein (FLAP) inhibitors
GB2431927B (en) 2005-11-04 2010-03-17 Amira Pharmaceuticals Inc 5-Lipoxygenase-activating protein (FLAP) inhibitors
US8399666B2 (en) 2005-11-04 2013-03-19 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein (FLAP) inhibitors
AU2009325091A1 (en) 2008-05-23 2010-06-17 Panmira Pharmaceuticals, Llc 5-lipoxygenase-activating protein inhibitor

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4358455A (en) 1980-12-23 1982-11-09 Merck & Co., Inc. Aralkylamindethanol heterocyclic compounds
US5019578A (en) 1987-11-27 1991-05-28 Merck & Co., Inc. β-adrenergic agonists
ATE154935T1 (de) * 1993-06-14 1997-07-15 Pfizer Zweite amine als antidiabetische mittel und für die behandlung von fettleibigkeit
IL113410A (en) * 1994-04-26 1999-11-30 Merck & Co Inc Substituted sulfonamides having an asymmetric center and pharmaceutical compositions containing them
CA2220399A1 (en) * 1995-05-10 1996-11-14 Pfizer Inc. .beta.-adrenergic agonists
EP0828712A1 (en) * 1995-05-10 1998-03-18 Pfizer Inc. Beta-adrenergic agonists

Also Published As

Publication number Publication date
HRP970612A2 (en) 1998-08-31
CA2270386A1 (en) 1998-05-22
PA8441401A1 (es) 2000-05-24
BR9712951A (pt) 1999-12-07
EA199900375A1 (ru) 1999-12-29
MA24401A1 (fr) 1998-07-01
BG103393A (en) 2000-07-31
TR199901063T2 (xx) 1999-08-23
JP3510635B2 (ja) 2004-03-29
CN1237160A (zh) 1999-12-01
AU4634697A (en) 1998-06-03
GT199700118A (es) 1999-05-05
AP9701147A0 (en) 1998-01-31
US6291489B1 (en) 2001-09-18
NO992296D0 (no) 1999-05-12
MY132507A (en) 2007-10-31
CO4930261A1 (es) 2000-06-27
CA2270386C (en) 2004-08-03
KR20000053314A (ko) 2000-08-25
ID18898A (id) 1998-05-20
EP0938476A1 (en) 1999-09-01
OA11044A (en) 2002-02-20
YU22099A (sh) 2001-09-28
JP2000504347A (ja) 2000-04-11
AP805A (en) 2000-01-28
NO992296L (no) 1999-05-12
IS5029A (is) 1999-04-16
AR010584A1 (es) 2000-06-28
WO1998021184A1 (en) 1998-05-22
EP0938476B1 (en) 2006-03-08
ZA9710186B (en) 1999-05-12
TNSN97172A1 (fr) 2005-03-15
ATE319687T1 (de) 2006-03-15
PE10299A1 (es) 1999-02-10
IL129688A0 (en) 2000-02-29
UY24774A1 (es) 1998-05-05

Similar Documents

Publication Publication Date Title
DE69704964D1 (de) Verfahren zur Herstellung von Acryloxypropylsilane
DE69713022D1 (de) Verfahren zur Herstellung von Unterkleidung
DE69802719D1 (de) Verfahren zur Herstellung von Acetalen
DE59707913D1 (de) Kontinuierliches Verfahren zur Herstellung von gamma- Aminopropyltrialkoxysilanen
DE69621491T2 (de) Verfahren zur Herstellung von Epsilon-Caprolactam
DE69802534D1 (de) Verfahren zur herstellung von fluorkohlenwasserstoffen
DE69703923D1 (de) Verfahren zur Herstellung von Polyester
DE69708508D1 (de) Verfahren zur Herstellung von geschweissten Strukturen
DE69510596T2 (de) Verfahren zur Herstellung von Organooxysilane
DE69424024D1 (de) Verfahren zur Herstellung von Laktamen
DE59608641D1 (de) Verfahren zur Herstellung von Nikotinsäureamid
DE69735433D1 (de) Verfahren zur herstellung von substituierten pyridinen
DE59707046D1 (de) Kontinuierliches Verfahren zur Herstellung von 4-Aminopiperidinen
DE69712157D1 (de) Verfahren zur Herstellung von Acrylnitril
DE59708227D1 (de) Verfahren zur Herstellung von feinstteiligen Kristallisationsprodukten
DE69611331T2 (de) Verfahren zur Herstellung von S-Phenyl-L-Cystein
DE69530176D1 (de) Verfahren zur Herstellung von Protein
DE59800130D1 (de) Verfahren zur Herstellung von Organosilazanen
DE69603243D1 (de) Verfahren zur Herstellung von Ethenylamiden
DE69707085T2 (de) Verfahren zur Herstellung von Homocystin
DE59801874D1 (de) Verfahren zur kontinuierlichen herstellung von dihydroxydiphenylalkanen
DE69700508T2 (de) Verfahren zur Herstellung von Organodisilanen
DE69702339T2 (de) Verfahren zur herstellung von cellulosealkanoatacetoacetaten
DE59501484D1 (de) Verfahren zur Herstellung von Salcomin
DE69708002D1 (de) Verfahren zur Herstellung von alpha-Brom,omega-Chloralkanen

Legal Events

Date Code Title Description
8332 No legal effect for de